Title

Biological Therapies for Atrial Fibrillation: Ready for Prime Time

UMMS Affiliation

Department of Medicine, Division of Cardiovascular Medicine

Publication Date

1-1-2016

Document Type

Article

Disciplines

Biological Factors | Cardiology | Cardiovascular Diseases | Genetic Phenomena | Genetics and Genomics | Pharmacology | Therapeutics

Abstract

Atrial fibrillation is a prominent cause of morbidity and mortality in developed countries. Treatment strategies center on controlling atrial rhythm or ventricular rate. The need for anticoagulation is an independent decision from the rate versus rhythm control debate. This review discusses novel biological strategies that have potential utility in the management of atrial fibrillation. Rate controlling strategies predominately rely on G-protein gene transfer to enhance cholinergic or suppress adrenergic signaling pathways in the atrioventricular node. Calcium channel blocking gene therapy and fibrosis enhancing cell therapy have also been reported. Rhythm controlling strategies focus on disrupting reentry by enhancing conduction or suppressing repolarization. Efforts to suppress inflammation and apoptosis are also under study. Resistance to blood clot formation has been shown with thrombomodulin. These strategies are in various stages of preclinical development.

Keywords

atrial fibrillation, gene therapy, cell therapy, atrioventricular node, conduction, repolarization

DOI of Published Version

10.1097/FJC.0000000000000293

Source

J Cardiovasc Pharmacol. 2016 Jan;67(1):19-25. doi: 10.1097/FJC.0000000000000293. Link to article on publisher's site

Journal/Book/Conference Title

Journal of cardiovascular pharmacology

Related Resources

Link to Article in PubMed

PubMed ID

26222989

Share

COinS